Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades15
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- IN BRIEF: Faron Pharmaceuticals Chair Tuomo Patsi adds to shareholding
2 Jul 2025 - Faron Pharmaceuticals appoints chief business officer
21 May 2025 - IN BRIEF: Faron Pharmaceuticals appoints new chief business officer
21 May 2025 - Faron enters financing arrangement with Heights Capital Management entity
3 Apr 2025 - UK shareholder meetings calendar - next 7 days
14 Mar 2025 - UK earnings, trading statements calendar - next 7 days
20 Feb 2025 - Faron Pharmaceuticals raises EUR12 million from oversubscribed placing
6 Feb 2025 - Faron identifies final patient in BEXMAB phase two study
31 Jan 2025
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
IN BRIEF: Faron Pharmaceuticals Chair Tuomo Patsi adds to shareholding
Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Non-Executive Chair Tuomo Patsi buys 21,500 ordinary shares at...
Faron Pharmaceuticals appoints chief business officer
(Sharecast News) - Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as th...
IN BRIEF: Faron Pharmaceuticals appoints new chief business officer
Faron Pharmaceuticals Ltd - Turku, Finland-based developer of cancer immunotherapies - Appoints Ralph Hughes as chief business officer, effective from...
Faron enters financing arrangement with Heights Capital Management entity
(Sharecast News) - Faron Pharmaceuticals announced on Thursday that it has entered into a financing arrangement with an entity managed by Heights Capi...
Faron Pharmaceuticals raises EUR12 million from oversubscribed placing
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial result...
Faron identifies final patient in BEXMAB phase two study
(Sharecast News) - Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study...
Follow the stocks
